Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04155 (
pS2
)
1,234
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) and related compounds modulate several endocrine systems by altering hormone synthesis, enhancing ligand metabolism, and down-regulating receptor levels/binding activity. Previous studies have demonstrated that TCDD inhibits the 17beta-estradiol (E2)-induction of
pS2
, a human breast cancer prognostic marker. This inhibition occurs at the gene expression level and is Ah receptor (AhR)-mediated. Analysis of the 5' regulatory region has identified three motifs which resemble dioxin response element (DRE) core sequences.
pS2
-regulated luciferase deletion constructs identified the DRE-like motif located at -527 to -514 as being required for TCDD-mediated suppression. A point mutation within this core motif (T-518C) abolished the inhibition by TCDD while UV-induced protein-DNA cross-linking and competitive gel retardation assays demonstrated AhR complex binding to this motif. Further study of this region also revealed an adjacent putative AP-1 site, diverging by one base pair from the consensus sequence. Gel retardation assays using
TPA
-treated MCF-7 cell nuclear extracts showed an induced complex binding to the AP-1-like site. Competition studies and antibody supershifts confirmed that the retarded complex consists of AP-1-like proteins.
pS2
-regulated luciferase constructs containing mutations specific to the AP-1-like motif greatly diminished the inducibility in response to E2. These results suggest that an interaction between AhR complexes and AP-1-like proteins may be responsible for TCDD-mediated inhibition of E2-induced
pS2
expression.
...
PMID:Identification of a motif within the 5' regulatory region of pS2 which is responsible for AP-1 binding and TCDD-mediated suppression. 916 78
Autonomous expression of progesterone receptors (PR) in human meningiomas is well established. To evaluate whether, similar to progesterone receptors, other estrogen-inducible proteins are also autonomously expressed in meningiomas, concentrations of
pS2
and cathepsin-D (Cath-D) were measured in 52 meningiomas. No
pS2 protein
was detectable in 52/52 tested meningiomas. The Cath-D protein was measurable in all 52 meningiomas, but the mean concentration of Cath-D in meningioma cytosols was 2.4-fold lower than that of a group of 54 breast tumors (p < 0.001). These results indicate that autonomous expression is a PR-related rather than an estrogen receptor-related phenomenon and, consequently, that estradiol is probably not responsible for PR synthesis in human meningiomas. To evaluate the role of other, non-estradiol-dependent signalling pathways in PR synthesis, the effects of EGF, Forskolin and phorbol ester on PR synthesis were tested in vitro. No PR was detectable after the addition of EGF to six different primary cultures. Forskolin and
TPA
addition caused a morphological change in meningioma cells, but did not induce PR or
pS2
synthesis in two different primary meningioma cultures. We conclude that PR synthesis in human meningiomas cannot be triggered by switching on the signalling pathways activated by these growth factors.
...
PMID:Progesterone receptor synthesis in human meningiomas: relation to the estrogen-induced proteins pS2 and cathepsin-D and influence of epidermal growth factor, Forskolin and phorbol ester in vitro. 968 Dec 95
Histone H3 phosphorylation is a downstream response to activation of the Ras/mitogen-activated protein kinase (MAPK) pathway. This modification is thought to have a role in chromatin remodeling and in the initiation of gene transcription. In MCF-7 breast cancer cells, we observed that phosphorylated histone H3 (phospho-H3) at Ser(10) but not Ser(28) increased with phorbol ester (12-O-tetradecanoylphorbol-13-acetate,
TPA
) treatment. Although phosphorylated extracellular signal-regulated kinase 1/2 levels in these cells cultured under estradiol deplete and replete conditions displayed no change, a significant induction was observed after
TPA
treatment. Furthermore, whereas both estradiol and
TPA
increased
trefoil factor 1
(
TFF1
) mRNA levels in these cells, only
TPA
-induced and not estradiol-induced
TFF1
expression was inhibited by the H3 kinase mitogen and stress activated protein kinase (MSK) inhibitor H89 and MAPK kinase inhibitor UO126, showing the involvement of the Ras/MAPK following
TPA
induction. Mutation of the activator protein 1 (AP-1) binding site abrogated the
TPA
-induced transcriptional response of the luciferase reporter gene under the control of the
TFF1
promoter, showing the requirement for the AP-1 site. In chromatin immunoprecipitation assays, estradiol treatment resulted in the association of the estrogen receptor-alpha (ERalpha) and acetylated H3 with the
TFF1
promoter. The levels of phospho-H3 and MSK1 associated with the
TFF1
promoter were moderately increased. In the presence of
TPA
, whereas ERalpha was not bound to the promoter, a strong association of acetylated and/or phospho-H3, MSK1, and c-Jun was observed. These results show that although both stimuli lead to
TFF1
gene activation, estradiol and
TPA
exert their effects on
TFF1
gene expression by different mechanisms.
...
PMID:Chromatin modification of the trefoil factor 1 gene in human breast cancer cells by the Ras/mitogen-activated protein kinase pathway. 1665 11
Circulating proteinic biomarkers are secreted by tumor cells or by their environmental cells and they have a variable specificity. In case of breast cancer, carcino-embryonic antigen (CEA) was for a long time the only circulating biomarker used. Nowadays, the most useful biomarkers measure circulating levels of fragments of MUC1-polymorphic epithelial mucin (MUC1-PEM): cancer antigen (CA) 15.3, mucin-like carcinoma-associated antigen (MCA), CA 27-29, CA 549... They are useful for general disease follow-up. Other circulating markers belonging to keratins (tissue polypeptide antigen,
TPA
, TPS or Cyfra 21.1) are correlated with proliferative activity of breast tumors. More recently, the measure of the c-erb B2 circulating part (extra cellular domain, ECD) was proposed as a prognostic biomarker for breast tumors with c-erb B2 overexpression. Moreover, the determination of urinary level of trefoil factor1 (PS2-
TFF1
) might be useful for the follow-up of hormonodependent breast cancers. The present review describes the clinical interest of these different circulating biomarkers in case of breast cancer, emphasizing their biological characteristics.
...
PMID:[Circulating proteinic biomarkers and breast cancer]. 1687 56
From the estrogen receptor containing breast cancer cell line MCF-7, several genes were shown to be hormone-inducible. The regulatory components involved in transcriptional regulation of one of them, the
pS2
gene, was determined using 1100 bp of its 5'-flanking region to drive the luciferase reporter gene in transiently transfected cells. MCF-7 breast cancer cells expressed 4-times as much luciferase compared to the pancreatic cell line PANG-I, that has ceased endogenous
pS2
expression, as well as the colonic cell line CX-1. In MCF-7,
pS2
-triggered reporter gene expression is greatly enhanced by the tumor promoter
TPA
, and, to some extend by EGF, demonstrating that
pS2
gene expression is due to specific trans-activating factors present in MCF-7, but not in PANG-I or CX-1. Cotransfection by estrogen receptor stimulated expression 10-fold, and combination with
TPA
had a synergistic effect, inducing expression 100-fold. EGF and estrogen receptor also work synergistically. The enhancing effect was abolished by deleting cis-acting regulatory sequences near the estrogen responsive element, suggesting that the corresponding regulatory factors may physically interact. This luciferase reporter gene assay quickly and conveniently tests the responsiveness to exogenous stimuli and the presence of specific transcription factors in different tumor cell lines.
...
PMID:Factors regulating pS2-reporter gene expression in MCF-7 breast cancer cell line. 2153 84